Heparin Market size was valued at USD 10.43 Billion in 2023 and is expected to cross USD 18.03 Billion by the end of 2036, expanding at more than 4.3% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of heparin is estimated at USD 10.83 Billion. The market growth is primarily driven by higher instances of cancer among the population. For instance, in 2040, the new cancer case count is anticipated to be nearly 28 million and the death toll is likely to reach around 16 million. Furthermore, the rising prevalence of coronary artery disease and venous thromboembolism is also fueling the growth of the heparin market over the forecast period.
Rising cases of accidents owing to vehicle crashes are expected to propel the market growth. As per the data of the World Health Organization, road accident is the most common cause of death of children and adults aged 5 to 29 and about 1.3 million people every year die in road accident globally. Furthermore, blood clotting during surgeries owing to several conditions also boosts the growth of the global heparin market.
Growth Drivers
Growing Pressure of Chronic Diseases on the World - Chronic diseases/Non-communicable diseases are currently the major cause of death among adults in almost all countries. This growing burden of chronic diseases is anticipated to boost the heparin market. As per the National Library of Medicine, every 3 in 5 deaths are attributed to a chronic disease such as cardiovascular disease, lung problem, diabetes, and others.
Rising Cases of Thromboembolism - In the United States, around 900,000 people are affected by pulmonary embolism or deep vein thrombosis. Moreover, up to 100,000 deaths are caused by venous thromboembolism globally.
Increase in Number of Cancer Patients - According to the World Health Organization, in 2020, around 2 million new cases of lung cancer and nearly 2.26 million of breast cancer were reported. Moreover, 10 million people died because of cancer.
Increased Cases of Injury and Deaths by Road Accidents - Fatal and non-fatal road accidents impose a burden of approximately 8 trillion dollars on the world’s economy and globally every day, around 3700 people die in a road accident.
Higher Instances of Renal Failure- For instance, globally, around 850 million people have acquired some kind of kidney problem.
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
4.3% |
|
Base Year Market Size (2023) |
USD 10.43 Billion |
|
Forecast Year Market Size (2036) |
USD 18.03 Billion |
|
Regional Scope |
|
Application (Deep Vein Thrombosis, Heart Attacks, Stroke, Atrial Fibrillation)
The heparin market is segmented and analyzed for demand and supply by application into deep vein thrombosis, heart attacks stroke, atrial fibrillation, and others. Out of all, the heart attacks segment is to garner the highest revenue by the end of 2036. This can be attributed to the rising prevalence of heart-related disorders across the globe. According to the World Health Organization, in 2019, around 18 million people die due to cardiovascular diseases and the global share of the CVD death is nearly 32%. Out of these deaths, about 85% were attributed to heart strokes and attacks. Therefore, the rise in cardiovascular problems is driving the growth of the segment. After heart strokes, the atrial fibrillation segment is anticipated to hold the position of second largest segment in the forecast period. This can be attributed to seeing a sizable amount of the global population suffering from this disease.
Route of Administration (Intravenous Infusion, Subcutaneous Injection)
The heparin market is segmented and analyzed for demand and supply by route of administration into subcutaneous injection and intravenous injection. The subcutaneous injection segment had the largest market share owing to the growing demand for home healthcare services, low hospitalized associated costs, and a few more properties like convenience in administration are factors driving the growth of this segment. The higher tolerance rate of patients for subcutaneous heparin performs as a benefit for the segment. The intravenous segment is anticipated to grow at a lucrative rate in the forecast year. The heparin especially unfractionated heparin is conducted through the intravenous route. It acts softly to prevent blood clots and also offers rapid entry into the bloodstream.
Our in-depth analysis of the global market includes the following segments:
|
By Product Type |
|
|
By Route of Administration |
|
|
By Application |
|
|
By End-User |
|
North American Market Forecast
The North American heparin market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2036. The market growth in the region is attributed to a higher number of people developing chronic kidney diseases, followed by surging healthcare expenditure. According to the Centers for Disease Control and Prevention, in 2021, 15% of adults in the United States have chronic kidney disease which is nearly 37 million people in the country. Moreover, rising instances of road accidents are expected to propel the market growth. As of January 2022, about 1 million road accidents took place in the United States.
APAC Market Statistics
The market in Asia Pacific is estimated to account for significant growth in the forecast period. The expansion in venous thromboembolism and cardiovascular diseases, increasing geriatric population, rising chronic disease in a large population, growing healthcare expenditure, and initiatives undertaken by the government of the region are the primary factors driving the growth of the heparin market. The major countries that cover the heparin market in the Asia Pacific region are China, Japan, India, South Korea, Malaysia, Australia, Indonesia, and the Rest of Asia Pacific.
Amcor Group GmbH has launched its latest OmniPack PET bottles to meet the requirements for e-commerce-ready packaging. Amcor has designed a family of stock PET bottles that help co-packers to meet demanding requirements for e-commerce-ready packaging.
ALPLA Group along with Voslaur has entered into a partnership to develop a new PET bottle for the Austrian market that will reduce the carbon footprint by 30% and reduces bottle weight by almost 90% in comparison to reusable substitute made up of glass.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?